<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Coronavirus (COVID-19) has been a life-changing experience for both individuals and institutions. The recent global events involving COVID-19 have placed a major burden on the economy and more specifically the health care sector. Unfortunately, an increase in the volume of acute care patients, secondary to COVID-19, has resulted in an interruption of care for patients with chronic illness. Cancer is one example of a nonacute illness that has taken a backseat [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Considering that prostate cancer is thought to be a relatively stable cancer when compared to other urological malignancies, it is somewhat fortunate that our practice consists mainly of prostate cancer patients. However, in recent years, it became evident that a delay in recently due diagnosis can translate into an increased rate of aggressive cancer, as evident after the delay in diagnosis, thanks to the USPSTF recommendations against screening. Actually, after 2012 we have a more high risk (HR) and high-volume diseases being were referred to our surgical practice [
 <xref ref-type="bibr" rid="CR2">2</xref>, 
 <xref ref-type="bibr" rid="CR3">3</xref>]. In response to this, we have had to deftly manage our practice so that we give preference to these patients. We adopted a risk-stratified approach in prioritizing patients while managing our practice.
</p>
